CXCL1 and breast cancer: It was also observed that CXCL1 knockdown in TAMs enhanced chemosensitivity of breast cancer to paclitaxel, and treatment with the autophagy inhibitor 3-Ma increased the chemosensitivity of paclitaxel when administered in conjunction with TAMs (Fig. 7A, B).